NASDAQ:DYN Dyne Therapeutics Q4 2024 Earnings Report $16.23 -0.91 (-5.31%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$16.22 -0.01 (-0.09%) As of 05:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dyne Therapeutics EPS ResultsActual EPS-$0.88Consensus EPS -$0.92Beat/MissBeat by +$0.04One Year Ago EPSN/ADyne Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADyne Therapeutics Announcement DetailsQuarterQ4 2024Date3/4/2025TimeBefore Market OpensConference Call DateThursday, February 27, 2025Conference Call Time7:30AM ETUpcoming EarningsDyne Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, October 29, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Dyne Therapeutics Earnings HeadlinesMyotonic Dystrophy Market Expected to Grow Rapidly During the Forecast Period (2026-2036) as Pipeline Therapies Address Unmet Medical Needs | DelveInsight4 hours ago | finance.yahoo.comDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 17, 2026 | globenewswire.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent. | Stansberry Research (Ad)Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 16, 2026 | americanbankingnews.comDyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)September 11, 2026 | theglobeandmail.comSee More Dyne Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email. Email Address About Dyne TherapeuticsDyne Therapeutics (NASDAQ:DYN) is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines. Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. These investigational therapies are intended to address disease-causing genetic mechanisms and improve the delivery of treatment to muscle cells. Founded in 2018 and headquartered in Waltham, Massachusetts, Dyne conducts research and clinical development activities intended to support patients with rare muscle diseases in the United States and other markets. The company is led by President and Chief Executive Officer John Wagner.View Dyne Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
